Axi-Cel OS Benefit Shown For Relapsed/Refractory Large B-Cell Lymphoma
From ASCO 2023 Annual Meeting:
Autologous anti-CD19 CAR T-cell therapy boosts overall survival in patients with early relapsed or refractory large B-cell lymphoma
Congress Scientific Watch
The Congress Scientific Watch provides ESMO Members with fresh comments and analysis from selected abstracts presented during major international Oncology meetings.
Login to start reading, or Join ESMO - All articles are Open Access after 6 months.
58 results
Final KEYNOTE-826 Survival Findings Support Pembrolizumab Use
From ASCO 2023 Annual Meeting:
Survival outcomes for persistent, recurrent or metastatic cervical cancer are significantly improved with the use of pembrolizumab alongside chemotherapy, regardless of bevacizumab therapy
Perioperative Pembrolizumab Strategy Improves Resectable NSCLC Outcomes
From ASCO 2023 Annual Meeting:
Interim KEYNOTE-671 findings demonstrate an event-free survival benefit with use of pembrolizumab before and after surgery for patients undergoing treatment for early-stage, non-small-cell lung cancer
IMpassion031: Atezolizumab Fails To Significantly Improve Early-Stage TNBC Survival
From ESMO Breast Cancer 2023:
Patients given neoadjuvant atezolizumab alongside chemotherapy for stage II–III triple-negative breast cancer are more likely to achieve pathological complete response but do not have better survival
Circulating Tumour DNA After Adjuvant Capecitabine Predicts Poor RFS For Early-Stage TNBC
From ESMO Breast Cancer 2023:
Patients who do not achieve a complete response to neoadjuvant therapy for early-stage triple-negative breast cancer and have ctDNA after additional capecitabine are at high risk of recurrence
ER-Low Breast Cancer May Follow ER-Negative Disease Patterns
From ESMO Breast Cancer 2023:
Patients with ER-low breast cancer may have disease with similar behaviours to those of their ER-negative counterparts
Obesity Impacts DFS For Postmenopausal Positive Breast Cancer Patients Aged Under 60
From ESMO Breast Cancer 2023:
Obesity is associated with poorer disease-free survival than normal weight after postmenopausal hormone receptor-positive breast cancer for women younger than 60 years, but may not affect older patients
CAPItello-291 PFS Benefits Confirmed Across Clinically Relevant Patient Subgroups
From ESMO Breast Cancer 2023:
The addition of capivasertib to fulvestrant improves progression-free survival for key subgroups of patients with hormone receptor-positive, HER2-negative advanced breast cancer resistant to aromatase inhibitors
Mutant-Specific PI3Kα Inhibitor Overcomes Toxicity Limitations of Drug Class
From the 2023 AACR Annual Meeting:
RLY-2608, a mutant-selective PI3Kα inhibitor, may offer patients with PIK3CA-mutant solid tumours a chance of treatment without experiencing the toxic effects of non-selective PI3Kα inhibition
FIGHT-207 Demonstrates Pemigatinib Activity Outside of Cholangiocarcinoma
From the 2023 AACR Annual Meeting:
Patients with gliomas, gynaecological tumours and pancreatic cancer could benefit from treatment with pemigatinib if they harbour an FGFR mutation
Olaparib Plus Ceralasertib May Offer Novel Paediatric Solid Tumour Option
From the 2023 AACR Annual Meeting:
Some children and adolescents with solid tumours harbouring gene alterations may benefit from a combination of olaparib plus ceralasertib
Early REGN5459 Findings Show Potential For Relapsed/Refractory Multiple Myeloma
From the 2023 AACR Annual Meeting:
Preliminary results suggest REGN5459 has efficacy as a treatment for patients with heavily pretreated multiple myeloma